Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
about
Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.Hematoma Enlargement Among Patients with Traumatic Brain Injury: Analysis of a Prospective Multicenter Clinical Trial.Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.
P2860
Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Recombinant activated factor V ...... mes and thromboembolic events.
@en
Recombinant activated factor V ...... mes and thromboembolic events.
@nl
type
label
Recombinant activated factor V ...... mes and thromboembolic events.
@en
Recombinant activated factor V ...... mes and thromboembolic events.
@nl
prefLabel
Recombinant activated factor V ...... mes and thromboembolic events.
@en
Recombinant activated factor V ...... mes and thromboembolic events.
@nl
P2093
P2860
P356
P1476
Recombinant activated factor V ...... mes and thromboembolic events.
@en
P2093
Christina L Candeloro
Donald F Brophy
Gretchen M Brophy
Jaime R Robles
P2860
P304
P356
10.1345/APH.1R729
P407
P577
2013-03-27T00:00:00Z